Perspective Therapeutics, Inc. (NYSE:CATX) Receives $12.75 Consensus Target Price from Brokerages

Shares of Perspective Therapeutics, Inc. (NYSE:CATX - Get Free Report) have been assigned an average rating of "Buy" from the eleven ratings firms that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and three have issued a strong buy rating on the company. The average 12-month target price among brokers that have covered the stock in the last year is $12.75.

Several research analysts have commented on the stock. Wedbush reissued an "outperform" rating and issued a $11.00 price target on shares of Perspective Therapeutics in a report on Wednesday, March 26th. Scotiabank began coverage on shares of Perspective Therapeutics in a report on Friday, March 7th. They issued a "sector outperform" rating and a $15.00 price target on the stock. Cantor Fitzgerald raised shares of Perspective Therapeutics to a "strong-buy" rating in a report on Tuesday, March 4th. Royal Bank of Canada decreased their price objective on Perspective Therapeutics from $16.00 to $15.00 and set an "outperform" rating on the stock in a report on Thursday, March 27th. Finally, Truist Financial lowered their target price on Perspective Therapeutics from $21.00 to $10.00 and set a "buy" rating for the company in a research note on Monday, April 7th.

Perspective Therapeutics Stock Up 3.6 %

Shares of Perspective Therapeutics stock traded up $0.09 on Tuesday, reaching $2.56. 713,082 shares of the company traded hands, compared to its average volume of 1,028,409. The company has a 50 day moving average of $2.28 and a 200 day moving average of $4.32. Perspective Therapeutics has a 52 week low of $1.60 and a 52 week high of $19.05.

Insider Transactions at Perspective Therapeutics

In other news, CEO Johan M. Spoor acquired 22,026 shares of the stock in a transaction on Friday, March 28th. The stock was acquired at an average price of $2.24 per share, with a total value of $49,338.24. Following the completion of the transaction, the chief executive officer now owns 59,383 shares of the company's stock, valued at $133,017.92. This represents a 58.96 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Juan Graham bought 33,333 shares of Perspective Therapeutics stock in a transaction dated Friday, March 28th. The stock was acquired at an average cost of $2.25 per share, for a total transaction of $74,999.25. Following the completion of the transaction, the chief financial officer now directly owns 35,354 shares in the company, valued at approximately $79,546.50. This trade represents a 1,649.33 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 115,696 shares of company stock valued at $256,344. Company insiders own 3.52% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the business. Y Intercept Hong Kong Ltd purchased a new position in shares of Perspective Therapeutics during the fourth quarter valued at approximately $33,000. Aigen Investment Management LP bought a new stake in Perspective Therapeutics in the fourth quarter worth $34,000. National Bank of Canada FI boosted its holdings in Perspective Therapeutics by 549,900.0% in the fourth quarter. National Bank of Canada FI now owns 11,000 shares of the company's stock worth $35,000 after acquiring an additional 10,998 shares in the last quarter. ProShare Advisors LLC grew its stake in shares of Perspective Therapeutics by 49.1% in the fourth quarter. ProShare Advisors LLC now owns 15,225 shares of the company's stock worth $49,000 after acquiring an additional 5,011 shares during the last quarter. Finally, Vontobel Holding Ltd. bought a new position in shares of Perspective Therapeutics during the fourth quarter valued at $51,000. 54.66% of the stock is owned by hedge funds and other institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.